The ZAS™ platform

The ZAS™ platform technology combines novel genes and existing drugs. ZGenes technology is based on a number of proprietary activator genes. These genes are optimized in different ways to activate specific anti-cancer drugs. ZGene combines FDA approved drugs with novel genes, thus minimizing costs and time for clinical development. The combination has resulted in the development of a variety of products, which is available for out-licensing.

Click on "ZGene Activation System" to read more...